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Undifferentiated connective tissue disease (UCTD) is a unique clinical entity, a potential 
forerunner of well-established systemic autoimmune/rheumatic diseases. UCTD is 
characterized by the presence of various clinical symptoms, as well as a diverse repertoire of 
autoantibodies, resembling systemic autoimmune diseases.  Since approximately one-third of 
these patients consequently transform into a full-blown systemic autoimmune/rheumatic 
disease, it is of major importance to assess pathogenic factors leading to this progression. In 
view of the fact that the serological and clinical picture of UCTD and systemic autoimmune 
diseases are very similar, it is assumed that analogous pathogenic factors perpetuate both 
disease entities. In systemic autoimmune conditions a quantitative and qualitative impairment 
of regulatory T cells have been shown previously and in parallel a relative dominance of pro-
inflammatory Th17 cells has been introduced. Moreover the imbalance between regulatory 
and Th17 cells plays a pivotal role in the initiation and propagation of UCTD. Additionally, 
we depict a cytokine imbalance, which give raise to a biased T-cell homeostasis from the 
UCTD phase throughout the fully developed systemic autoimmune disease stage. The levels 
of IL-6, IL-12, IL-17, IL-23 and IFN- were pathologically increased with a parallel reduction 
of IL-10. We believe that the assessment of Th17/Treg cell ratio, as well as the simultaneous 
quantitation of cytokines may give a useful diagnostic tool at the early UCTD stage to identify 
patients with a higher chance of consecutive disease progression towards serious systemic 
autoimmune diseases. Moreover, the early-targeted immunomodulating therapy in these 
patients may decelerate, or even stop this progression, before the development of serious 
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Undifferentiated connective tissue disease (UCTD) 
Undifferentiated connective tissue disease (UCTD) is a unique clinical entity, a potential 
forerunner of a subsequentially developing full-blown systemic autoimmune/rheumatic 
disease. UCTD is characterized by the presence of various clinical symptoms, resembling 
rheumatic diseases, as well as a diverse repertoire of autoantibodies. The most common 
clinical symptoms of the disease include Raynaud's phenomenon, fever, arthritis, serositis, 
(pleuritis, pericarditis), sicca symptoms, skin involvement (photosensitivity, rash), central and 
peripheral nervous system symptoms, vasculitis, pulmonary involvement, myositis, and 
accelerated atherosclerosis [1]. The serological abnormalities can include the presence of the 
following autoantibodies: anti-nuclear (ANA), anti-dsDNA, -Sm, -RNP, -SSA, -SSB, -Scl-70, 
-centromere, -Jo1, or -PM-Scl, amongst others [1]. However, this clinical-serologic 
constellation does not fulfill the diagnostic criteria of any well-defined rheumatic, systemic 
autoimmune diseases, amongst others rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE), Sjögren’s syndrome, idiopathic inflammatory myopathies (IIMs), 
mixed connective tissue disease (MCTD), or systemic sclerosis (SSc) [2-6]. The most 
important clinical feature of UCTD is that over one-third of these patients consequently 
transform into a full-blown systemic autoimmune/rheumatic disease [1].  In our previous 
study where we followed-up 665 UCTD patients for 5 years and showed that 34.5% of these 
patients developed a well-defined systemic autoimmune disease, with the following end-
disease progressions: 38% RA, 20% Sjögren's syndrome, 12% SLE, 11% MCTD, 10 systemic 
vasculitis, 8% progressive SSc and 1% IIMs [1]. The highest probability of evolution to a 




































































The pathogenesis of UCTD 
As we have depicted previously UCTD both in clinical symptoms and serologically resembles 
systemic autoimmune diseases, which raises the possibility that similar factors are involved in 
the pathogenesis of these clinical entities. Moreover, since UCTD can be the forerunner of 
subsequentially developing rheumatic diseases it is plausible that the escalation and intricate 
interplay of certain pathogenic factors in the UCTD stage lead to disease progression. UCTD 
and fully developed systemic autoimmune diseases are typically multi-etiological entities, 
where genetic, environmental abnormalities along with derailed immunoregulatory processes 
contribute to the development of the disease. In the healthy immune system, various tolerance 
mechanisms, such as activation-induced cell death, the functional inertness, denoted as 
anergy, or clonal ignorance play a crucial role to prevent the activation of self-reactive 
lymphocytes [7]. In autoimmune conditions with faulty tolerance mechanisms, self-reactive 
lymphocytes may not be subjected to peripheral deletion, or anergy raising the possibility of 
the survival and activation of autoreactive T and B cells upon autoantigen encounter [8-10]. 
However, there is a fine line between autoimmune processes, which also appear in healthy 
individuals and manifested autoimmune diseases. In autoimmune diseases, one or several 
tolerance mechanisms permanently fail due to the constellation of various environmental 
factors, specific HLA- and non-HLA genes and derailed immunoregulatory processes, leading 
to the persistence of self-reactive T and B cell clones, and ultimately organ damage [10,11]. 
Since similar clinical and pathogenic features can be found between UCTD and developed 
systemic autoimmune diseases we hypothesized that immunoregulatory abnormalities and/or 
the imbalance of immunoregulatory and inflammatory processes at the UCTD stage could 




































































The role of regulatory T cells in systemic autoimmune diseases and UCTD 
The balance of pro- and anti-inflammatory mechanisms is crucial to maintain the antigenic 
integrity of the individual, yet must effectively eliminate pathogens. On the anti-inflammatory 
side, several characteristic cell populations exist, which have the capability to suppress 
immune and autoimmune processes once they have developed. One important group of such 
immunoregulatory cells is denoted as regulatory T cells (Tregs). Tregs derive either from the 
thymus [CD4+CD25
bright
FoxP3+ natural Tregs (nTregs)] or in the peripheral blood [IL-10, or 
TGF-b producing Type-1 regulatory T-cells (Tr1)] [12]. It is reasonable to speculate that 
when regulatory T-cells are reduced in numbers or functionally impaired, pro-inflammatory 
immune responses are evoked, and upon susceptible genetic background, autoimmune 
processes can occur, leading to the spontaneous development of various autoimmune diseases. 
In line with this hypothesis, previous studies conducted on patients with systemic 
autoimmune and rheumatic disease described that the selective decrease in the number of 
Tregs or, alternatively, a diminished suppressor function of Tregs are characteristic to these 
diseases  (e.g. SLE, MCTD, Sjögren’s syndrome or RA [13-17]. These data indicate that in 
patients with established autoimmune conditions a well-characterized quantitative and/or 
qualitative impairment of the regulatory T-cell pool exists.  
 As a natural follow-up to these findings, we previously investigated the regulatory T 
cell pool of patients with UCTD [18]. In these patients, the assessment of Treg cells showed 
that the percentage and absolute number of CD4+CD25
bright
FoxP3+, natural Tregs were 
diminished in UCTD patients compared with healthy controls, while the number of CD4+IL-
10+, inducible Tregs was increased [18]. This progressive divergent shift in natural and 
induced T-regulatory cells clearly predicted the transition from the undifferentiated 



































































Interestingly, we and others have described that in patients with active systemic autoimmune 
diseases, such as SLE, or MCTD, the frequency of CD4+CD25
bright
FoxP3+ Tregs was found 
to be decreased compared to healthy individuals, or interestingly in patients with an inactive 
disease state [13,15,19]. The other major regulatory T cell subset, denoted as IL-10 producing 
Type-1 regulatory T-cells (CD4+IL-10+, Tr1) has been implicated in various autoimmune 
diseases [20]. IL-10 is a multifunctional cytokine that can suppress the IFN-γ production of 
Th1 cells and regulate growth and/or differentiation of various T cell types, B cells, or NK 
cells [21,22]. In relation to this we discovered a significant increase in Tr1s when UCTD 
patients were compared with healthy controls, and we found further increase in patients who 
progressed into definitive systemic autoimmune diseases. This could be interpreted as a 
compensatory mechanism to down-modulate the effects of the observed IFN-γ overproduction 
[18].  
Th17 cells and the Th17/Treg ratio in systemic autoimmune diseases and UCTD 
On the pro-inflammatory side, T-cells have the ability to differentiate into IL-17-producing T 
helper cells, denoted as Th17 cells, and this differentiation is independent of Th1 or Th2 cell 
development [23,24]. Th17 cells recruit neutrophils and macrophages to the site of 
inflammation; therefore they are crucial in pro-inflammatory immunological processes, in the 
combat against pathogens, mostly against extracellular pathogens [24]. Dysregulated 
synthesis and increased levels of Th17 cells have been associated with numerous 
inflammatory conditions, as well as with autoimmune diseases. Amongst others, increased 
levels of IL-17 has been shown in the sera, synovial fluids and synovial biopsies of most RA 
patients, while osteoarthrosis, as a control, non-inflammatory population, showed no 
increased levels of this cytokine [25,26]. Furthermore, emerging data show a body of 



































































nephritis [27,28]. Regarding an important systemic autoimmune disease, in patients with 
Sjögren’s syndrome, IL-17 has been shown to play a pivotal role in the pathogenesis both in 
the peripheral blood, and the cytokine can be found with increased levels in the affected 
salivary glands [29,30].  
 It is interesting to speculate on what initiates and drives the shift in balance of the 
Th17 and regulatory T-cells in autoimmune conditions. Regulatory T-cells develop in the 
thymus and participate in the maintenance of peripheral tolerance. As we saw, in systemic 
autoimmune diseases the circulating and local skewed cytokine milieu alters the suppressive 
function of these cells [31]. In affected organs, at the histological site of inflammation, a 
cytokine imbalance is present, with a predominance of IL-6 and TGF-b, which favor the 
development of Th17 cells. Th17 cells are pivotal in the initialization and progression of 
inflammatory processes, rather than Tregs; in addition higher concentrations of TNF-a 
downmodulates the function of Tregs [31]. 
 Since altered Th17 and regulatory T cell ratios may play a pathogenic role by tipping 
the fine balance toward enhanced immune reactivity, the disruption of this equilibrium has 
been studied in various systemic autoimmune conditions [32-35]. In order to assess whether a 
shift in the cytokine homeostasis exists in autoimmune conditions, fueling the predominance 
of pro-inflammatory cells vs. immunoregulatory T-cells, we have measured a broad spectrum 





































































Cytokine imbalance, regulatory/effector cells in various well-defined systemic 
autoimmune and rheumatic diseases 
Primary Sjögren's syndrome (pSS) 
The clinical picture and immunocompetent-cell distribution of pSS 
 Primary Sjögren's syndrome (pSS) is a chronic, slowly progressive, systemic autoimmune 
disease that predominantly affecting middle-aged women, although it can be seen in people of 
all ages, including children [42]. pSS is characterized by mononuclear infiltration and 
destruction of the exocrine glands, resulting in dry mouth, keratoconjunctivitis sicca and the 
presence of other exocrinopathic symptoms, affecting various organs [42]. In the 
pathogenesis, a variety of native and adaptive cellular and humoral autoimmune processes 
have been described previously [42,43]. On the adaptive immune system’s side, different 
subsets of T and B lymphocytes and monocytes contribute to the pathogenesis. Increased cell 
activation, uncontrolled apoptotic processes, and immune response are partly driven by a 
skewed cytokine milieu contributing to the pathogenesis of the disease [43,44]. Besides intra-
glandular cytokines and chemokines, a group of peripheral cytokines, chemokines and growth 
factors have been implicated in the pathogenesis of pSS, contributing to the perpetuation of 
the cellular and humoral autoimmune processes, leading to the pathognomonic clinical picture 
[44-47]. In our previous study we assessed how certain peripheral immune parameters reflect 
the inflammatory alterations in patients with pSS, determined lymphocyte subpopulations and 
their state of activation from peripheral blood, evaluating both soluble serum T-helper 
(Th)1/Th2-type cytokines, as well as intracytoplasmic cytokines [48]. We found that the 
skewed T-cell subsets and cytokine imbalance play important roles in an orchestrated 



































































activated T cells (CD3+/CD69+ T lymphocytes), compared to healthy individuals [48]. The 
assessment of naïve vs. memory CD4+ and CD8+ T cells, we could identify a clear shift 
towards the memory phenotype in both T cell subsets. Th0 and Th1 cell numbers were 
increased in patients compared to controls. Concerning cells of the innate immune system, 
NK cell and NK T-cell percentages were elevated in pSS patients.  
Cytokine imbalance in the pathogenesis of pSS 
In order to shed light, which cytokines might be responsible for the aforementioned cellular 
shifts we measured serum cytokines in patients and healthy individuals in parallell. 
Interestingly we found that among circulating cytokines, interferon (IFN)-gamma was high, 
whereas interleukin (IL)-10 was decreased in patients with pSS [48]. In addition, us and 
others have evaluated changes in regulatory cells and a wide spectrum of serum cytokine in 
pSS patients which seemed beneficial to cluster and subgroup patients with pSS [30,41,49-
51].  
The great advantage of assessing various cytokines in patients with systemic autoimmune and 
rheumatic diseases is that the univariate and/or multivariate analyses of these cytokines aids to 
create and identify patient subsets in diseases, previously thought to be homogeneous. In line 
with this approach, we have previously showed that circulating cytokines have the ability to 
distinguish pSS patients with ectopic salivary gland germinal centers, a possible forerunner of 
lymphoma development in the disease [30,41,50]. In this study, univariate analysis 
demonstrated that serum levels of a broad spectrum of immune and inflammatory modulating 
cytokines are upregulated in both pSS patient groups (pSS patients with, or without ectopic 
germinal center formation), relative to unaffected controls: IL-1beta, IL-2, IL-6, IL-15, IFN-
gamma and CCL4 (MIP-1beta) [30]. pSS patients with ectopic germinal center formation 



































































alpha, CCL3 (MIP-1alpha), CCL11 (Eotaxin) and B-cell activating factor (BAFF/BLyS), 
while germinal center positive and negative pSS patients differed in CCL2 (MCP-1) 
expression. Discriminant function analysis (DFA), a multivariate discrimination method that 
uses observed differences to characterize groups when casual relationships are not well 
understood, was employed to identify a subset of these biomarkers that maximally 
discriminate among germinal center positive and negative, as well as healthy individuals. The 
biomarker having the strongest discriminatory power identified by DFA were CCL11 
(Eotaxin), IFN-gamma, as well as BAFF/BLyS [30]. These data indicate that the continuous 
monitoring of these biomarkers might aid in identifying the development of ectopic germinal 




Systemic sclerosis (SSc) is a systemic disease of autoimmune pathogenesis, characterized by 
excessive extracellular matrix deposition and damage of the small blood vessels. (SSc) is 
associated with endothelial cell dysfunction, where classically the microvasculature is 
affected. The hallmarks of the disease are inflammatory processes, dominantly in the skin and 
visceral organs, such as the heart, lungs, or kidneys [52,53]. The key role of the innate and 
adaptive immune system has been depicted in the pathogenesis of SSc [54-57]. Disorders of 
the immune system lead to chronic inflammatory processes, abnormal T cell activation, B cell 
abnormalities, abundant production of proinflammatory cytokines (e.g. IL-4), and the 
production of characteristic autoantibodies including anti-centromere antibodies in limited 
SSc and anti-topoisomerase 1 and anti-RNA polymerase I/III antibodies in diffuse SSc. 



































































perpetuation of the disease [56,57]. In SSc patients increased levels of circulating Th17 cell 
have been described, along with elevated IL-17 serum concentrations [58,59]. On the helper T 
cell side, an altered balance of the Th1 and Th2 cytokine profile may also be responsible for 
the development of fibrosis [60]. Previously we have depicted a wide spectrum of peripheral 
immune-competent cell types, reflecting overall disturbances in immune homeostasis, 
characteristic of systemic sclerosis [61]. We found that patients with SSc had higher 
percentages of activated T cells, reflected by increased ratio of CD3+/HLA-DR+ cells. 
Comparing naive vs. memory subsets of CD4+ and CD8+ T cells, a shift towards central 
memory phenotype was observed. We saw an imbalance of various immune-competent 
celltypes of the innate immune system characterized by abnormal levels of NK and NKT 
cells.  
 
Regulatory T-cells and the cytokine milieu in the pathogenesis of SSc 
We depicted a shift between the effector and regulatory T cell level in SSc. Increased Th-17 
cell percentages, together with decreased levels of Th1, as well as regulatory T cell subsets, 
IL-10 producing Tr1 cells (CD4+IL-10+ T-cells), and CD4+CD25+FOXp3+ Treg cell were 
characteristic to these patients [61]. We also found decreased IL-10 levels in SSc. Besides the 
quantitative differences of regulatory cells between patients and controls, the functional 
assessment of Tregs identified that the suppressor activity of CD4+CD25+FOXP3+ Treg cells 
was clearly decreased in SSc, compared to healthy individuals. Our data suggest that the 
increased Th17/Treg ratio and the altered regulatory function of CD4+CD25+FOXP3+ Treg 
cells play an important role in the development and progression of SSc. Moreover, our study 
identified the potential role of the decreased presence of IL-10-producing Tr1 cells (along 
with lower IL-10 serum levels) in the progression of disproportionate immune responses in 



































































competent cells and peripheral cytokines aids in the understanding the pathogenesis of these 
diseases, also serves as useful disease activity markers and helps to sub-categorize 
autoimmune diseases. The Th17 cell and regulatory T cell imbalance, along with impaired 
circulating cytokine profile gives a good ground to use these parameters for therapy response 
assessment in SSc. Extracorporeal photochemotherapy (ECP) is a useful therapeutic modality 
in SSc, therefore we enrolled patients with diffuse cutaneous SSc, whom received 12 ECP 
treatments in total and assessed various immunocompetent celltypes, including regulatory 
cells and Th17 cells using intracellular cytokine staining [62]. We could see significant 
changes in these parameters following treatment. After a series of ECP, the percentages and 
numbers of peripheral Th17 cells decreased, we observed a clear increase in Tr1 and Treg cell 
numbers, and interestingly we could identify a functional improvement of Tregs, as reflected 
by the recovered suppressor capacity of Treg cells. Moreover, we found a positive correlation 
between the reduction of IL-17 levels and skin thickness, an objective measure of 
improvement in SSc. Concerning serum cytokines, chemokines and growth factors, levels of 
CCL2 and TGF-beta decreased, while the concentration of IL-10, IL-1-receptor-alpha, and 
hepatocyte growth factor elevated during the therapy [62]. ECP had a clear effect on 
lymphocyte activation. We observed a significant negative correlation between the changes in 
peripheral activated CD95+ T cell and CD4+CD25+ Treg cell levels. We found negative 
correlations between CD69+ and HLA-DR+ T cells and the functional ability of the 
CD4+CD25+ Treg cells following a series of ECP treatment. The initial increase of CD95+ 
expression in SSc reflects a state of lymphocyte activation during autoimmune processes, 
which can be effectively attenuated by the restoration of regulative T cell numbers and 
functions as the result of ECP therapy [63]. These results clearly indicate that the assessment 
of Th17 and regulatory T cell subsets along with soluble cytokines aids in the patient follow-




































































Mixed Connective Tissue Disease 
Clinical picture, effector- and regulatory-T cell profile of MCTD patients 
In Mixed connective tissue disease (MCTD) the most frequently observed symptoms are 
arthritis, Raynaud’s phenomenon, myositis, esophageal dysmotility, and acrosclerosis along 
with the presence of autoantibodies reactive with U1 small nuclear RNP (U1RNP) 
autoantigens [64-66]. Long-term follow-up studies reveal that other symptoms, such as 
serositis (pleuritis, pericarditis), pulmonary involvement, skin involvement, neuropsychiatric 
disease, and glomerulonephritis may also develop in this systemic autoimmune disease [67-
71]. Previously we assessed serum cytokines and intracellular cytokine production of CD4+ 
and CD8+ T cells in patients with MCTD [72]. Serum concentrations of both type 1 and type 
2 cytokines were significantly higher in patients with MCTD than in healthy controls. In 
patients with active MCTD, the percentage of CD8+/IFN-gamma+, cytotoxic type-1 T 
lymphocytes was significantly increased compared to its level in inactive disease, or healthy 
individuals. IL-4 expression of CD4+ T cells (representing Th2 cells) was scarcely detectable 
in MCTD. A higher percentage of CD8+/IL-4+, cytotoxic type 2 T cells were detected in 
patients, especially in those with active disease, compared to controls. The percentage of IL-
10-producing CD4+ and CD8+ T cells was higher in patients than in controls. Again, CD4+ 
and CD8+ T cells from patients with active MCTD produced significantly more IL-10 than 
cells in patients with inactive disease or in healthy individuals [72]. These findings support 
the idea that MCTD is characterized by a wide spectrum of T cell abnormalities, which 
becomes explicit in the active phase of the disease. Concerning the role of immunoregulatory 
abnormalities in the pathogenesis, we assessed CD4+CD25+ regulatory T-cells in patients 



































































diseases, the percentage and the absolute number of CD4+CD25+high Treg cells were lower 
in patients than in healthy controls which further decreased in patients with active disease. 
Interestingly, we saw an increase in the percentage and absolute number of CD4+IL-10+ Tr1 
cells in patients with MCTD compared to healthy controls. The percentage of Tr1 cells was 
higher in the active stage of MCTD than in the inactive stage. The decrease in the number of 
CD4+CD25+high Treg cells in an important factor in the immunoregulatory disturbance in 
patients with MCTD. We believe that elevated Tr1 cell percentages could be a compensatory 
mechanism aiming to restore the balance between type 1 and type 2 cytokines in MCTD [73].  
Characterisation of serum cytokines and regulatory cells in MCTD  
As we discussed previously the assessment of regulatory cells and serum cytokine monitoring 
can be a useful tool in disease sub-categorization. In order to depict the value of cytokine 
measurement and regulatory cell assessment in MCTD, we investigate the frequency of 
sensorineural hearing loss (SNHL) in patients with MCTD and evaluated various 
immunological parameters in patients with, or without this inner ear disorder. Serum levels of 
IFN-gamma and TNF-alpha were increased in MCTD patients with SNHL compared to 
patients without SNHL. The absolute number of Tregs was lower compared to patients 
without SNHL. The decreased levels of regulatory T cells, along with the increased 
expression of pro-inflammatory cytokines may play a role in the pathogenesis of immune 
mediated inner ear disorders in MCTD [74].  
In another approach in order to use cytokine assessment in disease profiling, we evaluated the 
vitamin D status in MCTD patients and assessed which clinical symptoms, laboratory 
parameters and endothelial cell markers are associated with low vitamin D levels. We found 
that vitamin D levels were inversely associated with serum IL-6, IL-23, and IL-10 cytokine 



































































media thickness, fibrinogen, total cholesterol and ApoA1 levels. The presence of 
cardiovascular diseases showed an inverse correlation with vitamin D status in MCTD. By 
assessing peripheral cytokines in MCTD we could identify that vitamin D insufficiency along 
with inflammatory parameters, reflected by increased serum pro-inflammatory cytokine levels 
may provoke cardiovascular events [75]. Serum and intracellular cytokine assessment, 
reflecting immune-regulatory abnormalities are valuable biomarkers to assess disease activity 
in MCTD, also capable of sub-categorizing these patients, as well.   
 
Systemic Lupus Erythematosus (SLE) 
Clinical picture and pathogenesis 
SLE is a heterogeneous, multi-etiological systemic autoimmune disease with various organ 
involvements, encompassing mild to moderate forms, and also severe, progressive variants 
[76-78]. The organ manifestations of the disease include dermatologic signs, arthritis, and 
serositis, as well as renal, neurologic, and hematologic disorders. Serologically, lupus is 
characterized by the presence of antinuclear antibodies (80–90 % of patients), double-
stranded DNA-directed autoantibodies (58–70 % of patients), and antibodies directed to other 
nuclear antigens, such as histones and small nuclear ribonucleoproteins (snRNP) in a minor 
group of patients.  
Cytokines and immune-regulatory defects 
Several cytokines have also been implicated in the pathogenesis of SLE, amongst others 
BAFF/BLyS, TNF-α, IFN-, IFN-, IL-12, IL-23, IL-18, IL-6, IL-10 and IL-17 forming a 
rationale also for therapeutic intervention in the disease [79,80]. 
Previous studies on gene polymorphisms in SLE risk genes identified the key roles of 



































































factor-5, (IRF5) has been shown to be linked to the increased production of interferon (IFN)-
α, and an autoimmune disease risk variant of signal transducer and activator of transcription 4  
(STAT4) causes increased sensitivity to IFN-α in patients with SLE [81,82]. The protein, 
encoded by tumor necrosis factor alpha-induced protein 3 gene (TNFAIP3), on the other hand, 
inhibits nuclear factor κB-dependent signaling and, thus, prevents inflammation that is caused 
by multiple cytokines [83]. Genetic variation, therefore, could help to explain the increases in 
a wide range of cytokine responses in SLE.   Recently, an interesting study evaluated changes 
in plasma concentrations of soluble mediators preceding clinically-defined disease flares in 
SLE. They found that patients with impending flare had significant alterations in a wide 
variety of soluble mediators at baseline with significantly higher levels of pro-inflammatory 
mediators, including Th1, Th2, and Th17-type cytokines, several weeks before clinical flare 
compared to clinically stable patients [84]. Levels of regulatory cytokines, including IL-10 
and TGF-β were higher in non-flare SLE patients, while baseline levels of soluble TNFRI, 
TNFRII, Fas, FasL, and CD40L were significantly greater in pre-flare patients. These findings 
support the idea that alterations in the balance between inflammatory and regulatory 
mediators may help identify patients at risk of disease flare and help decipher SLE pathogenic 
mechanisms [84]. Concerning the role of regulatory T cells in SLE, most studies point to a 
reduction in Treg cell number and function in SLE [85-87]. The role of Th17 cells has been 
described in the pathogenesis of SLE and several studies have reported an increase in Th17 
cells and IL17 in SLE, and in particular with disease flare [88-90]. The Th17 and Treg ratio 
indicates that SLE is associated with a reduction in the levels and function of 
immunosuppressive Treg cells together with an increase in the pro-inflammatory Th17 cells 
[91]. Table 1. summarizes the relevant findings in cytokine imbalance and regulatory/effector 




































































In UCTD the Th17/Treg ratio signifies progression towards well-defined systemic 
autoimmune diseases 
As we have illustrated, in all these various patient groups with systemic autoimmune 
conditions, we could identify a circulating cytokine imbalance, clearly reflecting a pro-
inflammatory milieu, moreover this particular cytokine imbalance and skewed pattern had the 
ability to promote the development of Th17 cells and the reduction in numbers/function of 
Tregs.  UCTD is a very unique clinical entity, representing the initial stages of systemic 
autoimmune diseases. UCTD patients can have various clinical symptoms, specific for 
autoimmune diseases, along with immunoserological abnormalities, yet they do not meet the 
standard criteria for any well-defined systemic autoimmune disease [42-45]. The clinical 
symptoms and the presence of the autoantibodies in UCTD suggest that many of the same 
immunological abnormalities that play a role in different well-defined systemic autoimmune 
diseases can also be involved in UCTD. Taken together, these findings point to that the 
Th17/Treg imbalance can be a good marker of a subsequent transition of these patients 
towards well-defined systemic autoimmune diseases. Accordingly,  we have assessed Th17 
cells, as well as regulatory T cell subsets in patients with UCTD, and identified whether the 
imbalance of these immunologically important cell types contribute to the development of a 
subsequent definitive systemic autoimmune and rheumatic diseases [46]. In this study we 
found that the most common clinical manifestations of these UCTD patients were 
polyarthritis, Raynaud’s phenomenon, and various skin symptoms, amongst others 
photosensitivity, malar rash and sclerodactily. Immunoserological abnormalities included 
positive ANA, ENA, RF, aSSA most frequently. The patients were followed-up for 5 years 
and changes of clinical activity, serological abnormalities, as well as the Th17 and Treg 



































































patients, when compared to healthy individuals. Moreover, Th17 cells were further increased 
in UCTD patients that subsequentially developed systemic autoimmune/rheumatic disease. 
Interestingly, the Th17/Treg ratio gradually increased from controls through UCTD patients, 
reaching the highest values in those, whom eventually progressed into definitive systemic 
autoimmune disease. The evaluation of the Th17/Treg could distinguish between UCTD 
patients with, or without subsequent systemic autoimmune disease progression in a very early 
UCTD stage. Of immunoserological markers, anti-CCP clearly associated with Th17/Treg 
ratios in connection with subsequent RA development. Concerning SLE-progression, anti-
SSA showed an apparent positive correlation with Th17 cell numbers. RA showed the most 
associations with various regulatory-cell biomarkers in several time-points of the disease 
development.  
A skewed cytokine milieu can be responsible for the altered Th17/Treg balance in 
UCTD 
Since previous findings in systemic autoimmune and rheumatic diseases indicated a skewed 
cytokine milieu which could fuel the shift of the Th17/Treg balance, we have assessed a 
variety of circulating cytokines in patients with UCTD and found that the levels of IL-6, IL-
12, IL-17, IL-23 and IFN- were pathologically increased with a parallel reduced level of IL-
10, which imbalance was normalized after alfacalcidiol treatment [47,48]. In parallel with the 
pro-inflammatory cytokine imbalance, increased Th17 with reduced Treg cell counts with a 
high Th17/Treg ratio was observed, which could be reverted by administering vitamin D to 
these patients [47,48]. These findings indicate that at a very early stage of systemic 
autoimmune disease development a shift of a cytokine imbalance, favoring a pro-
inflammatory milieu is present, contributing to a biased Th17/Treg distribution, which further 



































































symptoms. Presumably this functions as a reverberating cycle, as the tissue damage increases 
further shift in the cytokine balance and a consequent regulatory/effector T-cell 
disequilibrium. Taken these findings together it seems that the simultaneous, opposing effect 
of Th17 cells and Tregs has a strong impact on immune homeostasis, deciding and controlling 
the development of autoimmunity in these patients. Figure 1. summarizes the pathways and 
interconnections between tissue damage, skewed cytokine milieu and their role in the 
development of regulatory T cell and Th17 cell imbalance in autoimmune conditions. 
Concluding remarks 
Finally we should emphasize that besides the background Th17/Treg imbalance and cytokine 
dysequilibrium, a diverse antibody repertoire is present and may drive the development of 
various organ symptoms, leading to various autoimmune diseases. What determines the type 
of antibody produced and the type of systemic autoimmune disease developed? Why does the 
process stop for many patients at the UCTD stage without further progression? We believe 
that immune-regulatory responses should be followed in patients closely in the UCTD stage, 
and presumably if only temporary or mild dysfunction can be seen in this machinery, that may 
not cause severe organ damage. To answer these questions is obviously a huge task, in which 
knowledge of genetics, regulatory cell functions, Th17 cell development and assessment of 
the cytokine milieu should be involved.  
 Our findings support the idea that the pathological immuno-regulatory balance 
between Th17 cells and T cells with regulatory capacity at least partly drives the development 
of UCTD and its progression to definitive systemic autoimmune, rheumatic diseases. 
Therefore the assessment of these parameters in patients with UCTD may be a useful marker 
to identify high-risk individuals with a potential for disease progression. We believe that the 



































































stage) by the administration of immunomodulating agents (e.g. alfacalcidiol, vitamin D 
derivates) can modulate the clinical picture, modify and decelerate the progression towards 
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Figure 1. Pathways and interconnections between tissue damage, skewed cytokine milieu and 






































































Table 1. Skewed cytokine balance, cellular and immunoregulatory abnormalities in 
UCTD and various systemic autoimmune diseases 





Immunoregulatory defects  
Reference 
Undifferentiated 
Connective Tissue Disease 
(UCTD) 
- Forerunner of well 
established systemic 
autoimmune diseases 
- UCTD shares clinical and 
serological manifestations 
with definite connective tissue 
diseases, but not fulfilling any 
of the existing classification 
criteria 
-Increased serum levels of 
IL-6, IL-12, IL-17, IL-23 
and IFN- 
-Diminished IL-10 
-percentage and absolute number 
of natural Tregs are diminished 
-CD4+IL10+, inducible Treg 
increased 
-progressive divergent shift 
between natural and inducible 
Tregs signify disease 
progression 
18,46-48 
Sjögren’s syndrome (pSS) - pSS is a common systemic 
autoimmune disease that 
primarily affects the exocrine 
glands and leads to decreased 
lachrymal and salivary 
secretion.  
- other systemic symptoms, 
denoted as extraglandular 
manifestations can also be 
found in a subset of patients 
-Elevated levels of IL-17 
in the serum and salivary 
glands 
-High serum IFN-, 
decreased IL-10 
-IL-1b, IL-2, IL-6, IL-15, 
IFN-, CCL4 are 
increased in patients  
-IL-4, IL-10, GM-CSF, 
IFN-a, IFN-, CCL3, 
CCL11, BAFF signifies 
ectopic germinal center 
positive patients 
-Increased proportion of 
activated T cells and memory 
CD4+/CD8+ 




Systemic sclerosis (SSc) - chronic autoimmune disease 
with vascular dysfunctions and 
fibrosis of the skin, vessel 
wall, musculoskeletal system 
and certain internal organs  
- commonly divided into 
limited and diffuse cutaneous 
forms, based on the extent of 
skin involvement 
- in diffuse cutaneous SSc, the 
rapid fibrotic processes result 
in progressive deterioration 
and atrophy of the skin and 
involved internal organs 
-Serum IL-17 elevated  
-Low serum levels of IL-
10  
-Th17 proportion increased 
-Tregs diminished (both natural 
and inducible subsets) 
-weaker Treg suppressor 
function  
-altered Th1/Th2 balance 
-increased activated T-cell 
frequency 
-shift towards central memory 
phenotype 
-NK, NKT abnormalities 
35,58-61 
Mixed Connective Tissue 
Disease (MCTD) 
- systemic autoimmune, 
inflammatory disorder, 
characterized by the 
simultaneous damage of 
multiple organs.  
- the most common symptoms 
are polyarthritis, the swelling 




arterial hypertension and 
interstitial lung disease 
-Both type I and type II 
cytokines are increased 
 
-Diminished natural Treg 
frequency 
- CD4+IL10+, inducible Treg 
increased 
-IFN--producing and IL-4-
producing CD8+ T cells are 
increased 
-diminished Th2 
-IL-10+CD4+ and IL-10+CD8+ 







































































- commonly affects women in 
child-bearing years   
- heterogeneous systemic 
autoimmune disease, which 
encompasses mild to moderate 
forms, and also severe, 
progressive variants  
- several organs can be 




respiratory and nervous 
systems  
-Increased IL-17 
- BAFF/BLyS, TNF-α, 
IFN-, IFN-, IL-12, IL-
23, IL-18, IL-6, IL-10 
play a role in the 
pathogenesis 
-IL-10 and TGF- is 
reduced, while soluble 
TNFRI, TNFRII, Fas, 
FasL, and CD40L is 
elevated in patients before 
disease flare  
-Reduced numbers of FoxP3+ 
natural Tregs 
-Increased ratio of Th17 plays a 
role in lupus development and 
lupus nephritis as well in 
patients with disease flares 
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